PersonAlisation of RelApse risk in autoimmune DISEase (PARADISE)

Purpose and goal

Autoimmune disease affects 10% of adults. Affected individuals receive standard treatment regimens for long time, even when the autoimmune response may no longer be detectable. The PARADISE consortium aims to develop a personalised tool to define the immune activation level and tailor the patient´s treatment, using vasculitis as disease model. The tool will integrate clinical data, biomarkers and smartphone-derived data to inform predictive algorithms. KTH, as partner, aims to find new candidate autoantibody biomarkers by applying high-throughput protein array technology.

Expected effects and result

We will develop a clinical prediction tool to tailor immunosuppressive drug dosage in autoimmune diseases. This will have immediate benefits for the patients at low risk, but who receive highdosage due to lack of effective prediction. This will reduce side effects, associated comorbidities, and the use of antibiotics, while improving quality of life. Society would benefit from this tool by increasing the effectiveness of service and reducing the need for crisis care, and returning individuals to productive lives. The reduction of drug usage will also bring economic benefit.

Planned approach and implementation

The PARADISE consortium work is organized in 7 work packages (WP1-7) and covers 36 months (M1-36). The distribution of existing data and samples from biobanks takes place M1-30 (WP1). Autoantibody and transcriptomic data will be collected M4-30 (WP2). Data integration is developed M1-10 and implemented till M36 (WP3). Predictive models and clinical tool covers M18-36 (WP4). Patient engagement and workshops (WP5), as well as Project Management (WP7) covers M1-36. Communications and future planning (WP6) take place primarily from M18, and the website runs throughout the project.